A role for the effects of preexisting antibody titers on clinical efficacy with AAV vectors was surmised early on, and most trials tested these as part of the clinical protocol. The pattern that emerged was that trials that targeted solid organs by direct injection (eg, intramuscular) or that delivered vector to compartments with limited access to circulating antibodies, such as the central nervous system (including the subretinal space), showed effective transduction even in the presence of detectable antibody titers, 10, 11 but that delivery of vector through the circulation was sensitive to even low levels of neutralizing antibodies. 1 Subsequent studies in animal models further delineated this observation. In mice, the use of human intravenous immunoglobulin to model preexisting neutralizing antibodies to AAV suggested that this in vivo model may be more sensitive than the in vitro cell-based assays, 12 and studies in non-human primates, which are natural hosts for AAV and thus have naturally occurring antibodies, documented that even low-titer neutralizing antibodies (determined in a cell-based in vitro assay) could fully block liver transduction when vector was infused intravenously. thus better suited for inclusion/exclusion criteria. 16 However, neutralizing assays (both in vivo and in vitro) rely on the ability of a reporter vector to transduce the target cells and mediate quantifiable expression levels that decrease proportionally to the amount of circulating transduction inhibitors. This poses a number of significant limitations to their standardization, as transduction efficiency is highly serotypedependent and, in general, the sensitivity of the assay decreases as the AAV dose increases, compromising the comparison of NAb titers between serotypes with distinct transduction efficiencies. As an example, the assay used by the authors to measure anti-AAV5 NAbs requires an MOI of 25 000, supplemented with etoposide, an agent that promotes transduction, 17 whereas the anti-AAV8 NAb assay uses an MOI of 200 with no requirement for agents like etoposide. 18 Other characteristics that impact NAb titers when evaluated using in vitro assays include the amount of serum used, the cell number on the plate and the reporter transgene. 16 In this regard, use of assays that do not rely on transduction performance, such as total antibody assays or the assay recently developed by Guo and colleagues, which relies on quantification of AAV binding to the target cells in vitro using a qPCR assay.
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Further compounding the intrinsic complexity of each assay are the differences in the AAV investigational products themselves, in terms of infectivity titers and content of empty capsids, both of which influence transduction performance and thus may affect the NAb titer.
Empty capsids, which contain the capsid but lack any packaged DNA, 
RELATIONSHIP DISCLOSURES
Dr. Anguela reports employment from Spark Therapeutics during the writing of the manuscript. In addition, Dr. Anguela is an inventor in the following patent applications pending to Spark Therapeutics:
WO2013158879A1, US20140336245A1, US20150023924A1, US2016 0375110A1, and WO2017075619A1. Dr. High reports personal fees and other from Spark Therapeutics, outside the submitted work.
AUTHOR CONTRIBUTION
Dr. High and Dr. Anguela jointly outlined the editorial, researched it, drafted it, and revised it.
